スタッフ紹介

助教結城 敏志

Satoshi Yuki

専門分野

臨床腫瘍学 [主に大腸がん/胃がん]
がんゲノム医療

助教 結城 敏志

学歴

1993年3月
釧路湖陵高等学校 卒業
1999年3月
弘前大学 医学部 医学科 卒業
2007年3月
北海道大学大学院 医学研究科 病態制御学専攻 医学博士課程 終了

職務経歴

1999年6月
北海道大学医学部附属病院 研修医 [第三内科/第二内科/第一内科]
2000年4月
NTT東日本札幌病院 研修医 [循環器内科/消化器内科]
2001年4月
釧路労災病院 内科 医師
2002年4月
網走厚生病院 内科 医師
2006年4月
北海道大学病院 第3内科 医員
2008年4月
北海道大学病院 第3内科 助教
2012年4月
北海道大学病院 消化器内科 助教

所属学会・資格

  • 日本内科学会 認定内科医
  • 日本臨床腫瘍学会
    がん薬物療法専門医・指導医・協議員・がん薬物療法専門医制度委員会 専門医部会 北海道支部代表
  • 日本遺伝性腫瘍学会
  • 日本癌治療学会
  • 日本胃癌学会
  • 日本がんサポーティブケア学会
  • 日本がん予防学会
  • 日本消化器病学会
  • 米国臨床腫瘍学会(ASCO) Active Member
  • 欧州臨床腫瘍学会(ESMO) Active Member
  • 日本がん治療認定医機構 がん治療認定医・暫定教育医

受賞歴

  • 2013年 Asia Pacific Cancer Conference:Young Investigator's Award
  • 2017年 第55回 日本癌治療学会 学術集会:優秀演題賞

業績
(英文のみ)

  1. Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M.
    Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
    Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223.
  2. Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M.
    One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
    Oncologist. 2019 Dec;24(12):1593-1600.
  3. Masuishi T, Taniguchi H, Kawakami T, Kawamoto Y, Kadowaki S, Onozawa Y, Muranaka T, Tajika M, Yasui H, Nakatsumi H, Yuki S, Muro K, Omae K, Komatsu Y, Yamazaki K.
    Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    ESMO Open. 2019 Nov;4(6):e000584.
  4. Fujii S, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.
    Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.
    Biomed Rep. 2019 Oct;11(4):171-180.
  5. Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K.
    Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    BMC Cancer. 2019 Mar 21;19(1):255.
  6. Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, Yoshino T, Komatsu Y, Sakamoto N, Okamoto W, Fujii S.
    Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
    Clin Colorectal Cancer. 2018 Sep;17(3):198-205.
  7. Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
    Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
    Oncology. 2018;94(5):289-296.
  8. Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C.
    S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
    Ann Oncol. 2018 Mar 1;29(3):624-631.
  9. Muranaka T, Komatsu Y, Yagisawa M, Sawada K, Harada K, Kawamoto Y, Nakatsumi H, Yuki S, Ono K, Kawahata S, Kobayashi Y, Sogabe S, Miyagishima T, Hatanaka K, Sasaki T, Dazai M, Iwanaga I, Ishiguro A, Nakamura M, Sakamoto N, Sakata Y.
    Protocol: Feasibility Study of Bolus 5-Fluorouracil+L-Leucovorin as Salvage Line Chemotherapy for Oral Fluorouracil-Resistant Unresectable Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group Study HGCSG1502
    J Clin Trials. 2017 Dec;7(6):1000337.
  10. Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y.
    Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    BMC Cancer. 2017 Dec 8;17(1):837.
  11. Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.
    Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Br J Cancer. 2017 Nov 7;117(10):1450-1458.
  12. Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N.
    Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    J Gastrointest Oncol. 2017 Jun;8(3):556-571.
  13. Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, Murai T, Matsuda C, Oba A, Itaya K, Sone T, Yagisawa M, Koike Y, Endo A, Tsukuda Y, Ono Y, Kudo T, Nagasaka A, Nishikawa S, Komatsu Y.
    A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01).
    Oncologist. 2017 May;22(5):592-600
  14. Muranaka T, Yuki S, Komatsu Y, Sawada K, Harada K, Kawamoto Y, Nakatsumi H, Sakamoto N.
    Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience.
    J Gastric Cancer. 2016 Sep;16(3):177-181.
  15. Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A.
    Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Gastric Cancer. 2016 Jan;19(1):183-91.
  16. Komatsu Y, Ishioka C, Shimada K, Yamada Y, Gamoh M, Sato A, Yamaguchi T, Yuki S, Morita S, Takahashi S, Goto R, Kurihara M.
    Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    BMC Cancer. 2015 Sep 9;15:626.
  17. Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y.
    An open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
    Cancer Sci. 2015 Jul;106(7):891-5.
  18. Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N.
    Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
    Future Oncol. 2015 Feb;11(4):617-27.
  19. Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, Hyodo I, Yachi Y, Onuma H, Ohtsu.
    A Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Invest New Drugs. 2014 Jun;32(3):473-80.
  20. Shitara K, Yuki S, Tahahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Oze I, Matsuo K, Muro K.
    Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    Br J Cancer. 2014 Jan 21;110(2):271-7.
  21. Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A.
    Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
    BMC Cancer. 2013 Sep 3;13:405.
  22. Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, Muro K.
    Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
    Cancer Res Clin Oncol. 2013 Apr;139(4):595-603.
  23. Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M.
    Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study.
    Chemotherapy. 2012;58(6):439-44.
  24. Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A.
    Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan.
    Jpn J Clin Oncol. 2012 Dec;42(12):1146-51.
  25. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y.
    Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
    Invest New Drugs. 2012 Oct;30(5):1950-7.
  26. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y.
    Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
    Acta Oncol. 2012 Sep;51(7):867-72.
  27. Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K.
    Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Invest New Drugs. 2012 Apr;30(2):787-93.
  28. Shitara K, Ura T, Matsuo K, Takahari D, Yokota T, Yuki S, Yoshida M, Utsunomiya S, Sato Y, Yamaura H, Kato M, Inaba Y, Tajika M, Kawai H, Yamazaki K, Komatsu Y, Muro K.
    Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
    Eur J Cancer. 2011 Dec;47(18):2673-80.
  29. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M.
    Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
    Oncology. 2011 Jun;80(1-2):70-5.
  30. Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M.
    Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Jpn J Clin Oncol. 2011 Apr;41(4):490-7.
  31. Shitara K, Oze I, Mizota A, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Yuki S, Komatsu Y, Matsuo K, Muro K.
    Randomized phase II study comparing dose escalated weekly paclitaxel vs.standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    Jpn J Clin Oncol. 2011 Feb;41(2):287-90.
  32. Yuki S, Komatsu Y, Fuse N, Kato T, Miyagishima T, Kudo M, Watanabe M, Tateyama M, Kunieda Y, Wakahama O, Sakata Y, Asaka M.
    Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
    Clin Drug Investig. 2010 Aug;30(4):243-9.
  33. Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Sakata Y, Asaka M.
    Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Adv Ther. 2010 Jul;27(7):483-92.
  34. Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Komatsu Y, Yuki S, Yoshida M, Takiuchi H, Utsunomiya S, Yatabe Y, Muro K.
    Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
    Jpn J Clin Oncol. 2010 Jul;40(7):699-701.
  35. Shitara K, Komatsu Y, Yuki S, Munakata M, Muto O, Shimaya S, Sakata Y.
    Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.
    Oncology. 2008 Sep;75(1-2):67-70.
  36. Komatsu Y, Takei M, Yuki S, Fuse N, Furukawa S, Kato T, Takeda H, Kato M, Asaka M.
    Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.
    J Chemother. 2005 Feb;17(1):111-4.
  37. Komatsu Y, Yuki S, Fuse N, Takei M, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Ohizumi H, Watanabe M, Akita H, Sakata Y, Asaka M.
    Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
    Jpn J Clin Oncol. 2005 Feb;35(2):88-9.

国際学会、筆頭演者のみ

  1. Yuki S, Bando H, Tsukada Y, Inamori K, Komatsu Y, Homma S, Uemura M, Kato T, Kotani D, Fukuoka S, Nakamura N, Fukui M, Wakabayashi M, Kojima M, Togashi Y, Sato A, Nishikawa H, Ito M, Yoshino T.
    Short-Term Results of VOLTAGE-A: Nivolumab Monotherapy and Subsequent Radical Surgery Following Preoperative Chemoradiotherapy in Patients with Microsatellite Stable and Microsatellite Instability- High Locally Advanced Rectal Cancer (EPOC 1504).
    The ESMO World Congress on Gastrointestinal Cancer 2020 VIRTUAL. WEB, Jul 1-4, 2020.
  2. Yuki S, Bando H, Tsukada Y, Inamori K, Komatsu Y, Homma S, Uemura M, Kato T, Kotani D, Fukuoka S, Nakamura N, Fukui M, Wakabayashi M, Kojima M, Togashi Y, Sato A, Nishikawa H, Ito M, Yoshino T.
    Short-Term Results of VOLTAGE-A: Nivolumab Monotherapy and Subsequent Radical Surgery Following Preoperative Chemoradiotherapy in Patients with Microsatellite Stable and Microsatellite Instability- High Locally Advanced Rectal Cancer.
    ASCO20 Virtual. WEB, May 29-31, 2020.
  3. Yuki S, Gamoh M, Denda T, Takashima A, Takahashi S, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Ishioka C, Komine K, Ouchi K, Morita S, Komatsu Y.
    Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).
    2020 Gastrointestinal Cancers Symposium. San Francisco, Jan 23-25, 2020.
  4. Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Tokunaga S, Emi Y, Makiyama A, Kawamoto Y, Komatsu Y, Shimokawa M, Saeki H, Oki E, Baba H, Maehara Y.
    Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B.
    ESMO 2018 Congress. Munich, Oct 19-23, 2018.
  5. Yuki S, Komatsu Y, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Shinohara T, Miyashita K, Ito Y, Taketomi A, Hirano S, Sakamoto N.
    NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons.
    The ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona, Jun 20-23, 2018.
  6. Yuki S, Shitara K, Kadowaki S, Minashi K, Takeno A, Hara H, Kajiwara T, Sunakawa Y, Iwasa S, Yamamoto Y, Nagashima F, Nakanishi R, Esaki T, Yoshikawa T, Nomura S, Kuwata T, Fujii S, Okamoto W, Ohtsu A, Yoshino T.
    The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Gastric Cancer (GC).
    2018 ASCO Annual Meeting. Chicago, Jun 1-5, 2018.
  7. Yuki S, Yamazaki K, Taniguchi H, Sunakawa Y, Kawazoe A, Kagawa Y, Kato K, Hara H, Denda T, Oki E, Moriwaki T, Shiozawa M, Satoh T, Kawakami H, Esaki T, Furuse J, Abe Y, Nomura S, Ohtsu A, Yoshino T.
    The Nationwide Screening Project on Plasma Angiogenesis-Related Mediators for Treatment Selection of Optimal Antiangiogenic Inhibitors in Metastatic Colorectal Cancer: GI-SCREEN CRC-Ukit.
    2018 Gastrointestinal Cancers Symposium. San Francisco, Jan 18-20, 2018.
  8. Yuki S, Kato T, Taniguchi H, Hamaguchi T, Akagi K, DendaT, Mizukami T, Oki E, Yamada T, Shiozawa M, Kudo T, Tamura T, Esaki T, Naruge D, Kajiwara T, Nomura S, Fujii S, Shitara K, Ohtsu A, Yoshino T.
    The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Colorectal Cancer.
    ESMO 2017 Congress. Madrid, Sep 8-12, 2017.
  9. Yuki S, Komatsu Y, Yagisawa M, Tsuji Y, Harada K, Hatanaka K, Okuda H, Hosokawa A, Ogawa K, Furukawa K, Minami S, Ishiguro A, Honda T, Ohta T, Dazai M, Eto K, Sasaki T, Nakajima J, Sakamoto N, Sakata Y.
    A Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer [HGCSG1503]: Updated analysis.
    ESMO 2017 Congress. Madrid, Sep 08-12, 2017.
  10. Yuki S, Komatsu Y, Muranaka T, Tsuji Y, Harada K, Ota Y, Hatanaka K, Okuda H, Sasaki T, Dazai M, Konno J, Nakamura M, Ohta T, Honda T, Ishiguro A, Muto O, Kato S, Sato A, Abe M, Eto K, Sakamoto N, Sakata Y.
    A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer [HGCSG1401]: Analysis of tumor location.
    The ESMO 19th World Congress on Gastrointestinal Cancer. Barcelona, Jun 28-Jul 1, 2017.
  11. Yuki S, Komatsu Y, Satake H, Miyamoto Y, Tanioka H, Tsuji A, Asayama M, Shiraishi T, Kotaka M, Makiyama A, Kashiwada T, Takeuchi N, Shimokawa M, Saeki H, Oki E, Emi Y, Baba H, Maehara Y.
    Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): [KSCC1402/HGCSG1402].
    ESMO 2016 Congress. Copenhagen, Oct 7-11, 2016.
  12. Yuki S, Komatsu Y, Muranaka T, Harada K, Sugiyama J, Tsuji Y, Ando T, Hosokawa A, Hatanaka K, Naruse H, Takahata T, Sato A, Kobayashi Y, Miyagishima T, Okuda H, Kudo M, Nakamura M, Hisai H, Sakamoto N, Sakata Y.
    Phase II trial of Panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on Cetuximab [HGCSG1101].
    ESMO 2016 Congress. Copenhagen, Oct 7-11, 2016.
  13. Yuki S, Komatsu Y, Nakatsumi H, Kawamoto Y, Muranaka T, Sawada K, Tsuji Y, Hosokawa A, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakamoto N, Sakata Y.
    Final analysis : Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -Comparison of administration interval in Cetuximab treatment.
    The ESMO 18th World Congress on Gastrointestinal Cancer. Barcelona, Jun 29-Jul 2, 2016.
  14. Yuki S, Nakatsumi H, Sawada K, Kato T, Meguro T, Nakamura M, Iwanaga I, Ehira N, Sonoda N, Kudo M, Kato K, Sogabe S, Amano T, Ono K, Sakamoto K, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y.
    Observational Cohort Study of First-line Bevacizumab with Oxaliplatin or Irinotecan and Fluoropyrimidines in Metastatic Colorectal Cancer: HGCSG0802: Analysis of early tumor shrinkage (ETS).
    2016 Gastrointestinal Cancers Symposium. San Francisco, Jan 21-23, 2016.
  15. Yuki S, Komatsu Y, Nakatsumi H, Muranaka T, Kobayashi Y, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Hisai H, Abe R, Sakamoto N, Oba K, Sakata Y.
    Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: Updated analysis of anti-tumor efficacy.
    ESMO Asia 2015. Singapore, Dec 18-21, 2015.
  16. Yuki S, Komatsu Y, Muranaka T, Hayashi H, Yoshida S, Ohta Y, Hatanaka K, Tsuji Y, Kawamoto Y, Yoshizaki K, Sato A, Eto K, Onodera K, Kato S, Nakamura M, Muto O, Abe M, Sato Y, Ishiguro A, Tateyama M, Okuda H, Sakamoto S, Sakata Y.
    A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer; the HGCSG1401 Study -First Report-.
    The ESMO 17th World Congress on Gastrointestinal Cancer. Barcelona, July 1-4, 2015.
  17. Yuki S, Yoshino T, Tsuchihara K, Shinozaki E, Muro K, Nishina T, Yamaguchi K, Akagi K, Yamazaki K, Yamanaka T, Nomura S, Fujii S, Esumi H, Abe Y, Ohtsu A.
    Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
    2015 ASCO Annual Meeting. Chicago, May 29-Jun 2, 2015.
  18. Yuki S, Nakatsumi H, Hayashi H, Fukushima H, Kato T, Meguro T, Nakamura M, Iwanaga I, Eto K, Sato A, Okuda H, Oba A, Miyagishima T, Muto O, Yabusaki S, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y.
    Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
    2015 Gastrointestinal Cancers Symposium. San Francisco, Jan 15-17, 2015.
  19. Yuki S, Komatsu Y, Harada K, Fukushima H, Sasaki T, Kobayashi Y, Tsuji Y, Naruse H, Okuda H, Takahashi Y, Hosokawa A, Konno J, Eto K, Kudo M, Kawamoto Y, Sonoda N, Sato Y, Uebayashi M, Kato T, Onodera M, Ohta T, Sakata Y.
    Analysis of Glasgow Prognostic Score (GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
    16th World Congress on Gastrointestinal Cancer. Barcelona, Jun 25-28, 2014.
  20. Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Dazai M, Sogabe S, Miyagishima T, Ichiguro A, Takahata T, Sato A, Kudo M, Kato S, Kato K, Iwanaga I, Ehira N, Uebayashi M, Sakata Y.
    Phase II trial of S-1 plus split Cisplatin (SSP) in patients with advanced gastric cancer [HGCSG0702]: Final report.
    2014 Gastrointestinal Cancers Symposium. San Francisco, Jan 16-18, 2014.
  21. Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Amano T, Nakamura M, Kudo M, Tateyama M, Hatanaka K, Saitoh S, Miyagishima T, Kato T, Kawamoto Y, Takagi T, Iwanaga I, Miyashita K, Onodera M, Sakata Y.
    The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies.
    2014 Gastrointestinal Cancers Symposium. San Francisco, Jan 16-18, 2014.
  22. Yuki S, Komatsu Y, Fukushima H, Doi A, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Eto K, Kudo M, Akakura N, Munakata M, Tateyama M, Sato Y, Miyagishima T, Uebayashi M, Sakata Y.
    Analysis of Kohne's prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
    22nd Asia Pacific Cancer Conference. Tianjin, Oct 31-Nov 2, 2013.
  23. Yuki S, Komatsu Y, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Sakata Y.
    Analysis of Kohne's prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
    European Cancer Congress 2013. Amsterdam, Sep 27-Oct 1, 2013.
  24. Yuki S, Komatsu Y, Fukushima H, Sasaki T, Amano T, Miyagishima T, Hatanaka K, Nakamura M, Tateyama M, Sakata Y.
    Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC) - Final analysis -: Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
    2013 Gastrointestinal Cancers Symposium. San Francisco, Jan 24-26, 2013.
  25. Yuki S, Shitara K, Takahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Oze I, Muro K.
    Preliminary safety data from a randomized phase II study comparing dose-escalated weekly paclitaxel versus standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    ESMO 2012 Congress. Vienna, Sep 28-Oct 02, 2012.
  26. Yuki S, Komatsu Y, Miyagishima T, Kato T, Hatanaka K, Nakamura M, Kudo M, Akakura N, Tateyama M, Sakata Y.
    Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer -Updated analysis-. Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
    2012 ASCO Annual Meeting. Chicago, Jun 1-5, 2012.
  27. Yuki S, Komatsu Y, Kawamoto Y, Tsuji Y, Naruse H, Hosokawa A, Kusumi T, Ishiguro A, Saito S, Sakata Y.
    Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of after Cetuximab refractory -.
    2012 Gastrointestinal Cancers Symposium. San Francisco, Jan 19-21, 2012.
  28. Yuki S, Komatsu Y, Kogawa T, Hatanaka K, Kusumi T, Fujikawa K.
    Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of some predictive markers -.
    21st Asia Pacific Cancer Conference. Kuala Lumpur, Nov 10-12, 2011.
  29. Yuki S, Nakatsumi H, Tateyama M, Uehata Y, Kudo M, Kato K, Miyagishima T, Uebayashi M, Asaka M, Komatsu Y.
    The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: an exploratory trial -HGCSG0703-.
    2011 Gastrointestinal Cancers Symposium. San Francisco, Jan 20-22, 2011.
  30. Yuki S, Shitara K, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Tajika M, Muro K.
    Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Wild-type KRAS Metastatic Colorectal cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines.
    2011 Gastrointestinal Cancers Symposium. San Francisco, Jan 20-22, 2011.
  31. Yuki S, Komatsu Y, Sogabe S, Iwanaga I, Kudo M, Miyagishima T, Nakamura M, Hatanaka K, Asaka M, Sakata Y.
    Phase II Study of Combination With Irinotecan and S-1 (IRIS) for Inoperable Recurrent Advanced Colorectal Cancer [HGCSG0302]. Final analysis.
    2009 Gastrointestinal Cancers Symposium. San Francisco, Jan 15-17, 2009.
  32. Yuki S, Komatsu Y, Machida N, Ozasa M, Nishi K, Miyagishima T, Kato T, Nakamura M, Asaka M, Sakata Y.
    Phase II Study of Combination With Irinotecan and S-1 (IRIS) for Inoperable Recurrent Advanced Colorectal Cancer [HGCSG0302]. Safety analysis.
    The European Cancer Conference (ECCO14). Barcelona, Sep 23-27, 2007.
  33. Yuki S, Komatsu Y, Fuse N, Tateyama M, Nishi K, Kato T, Kudo M, Miyagishima T, Asaka M, Sakata Y.
    Phase I/II study of docetaxel, cisplatin and 5-fluorouracil (TPF) as first-line chemotherapy in Japanese patients with advanced esophageal cancer.
    2006 Gastrointestinal Cancers Symposium. San Francisco, Jan 26-28, 2006.